Multidisciplinary Association for Psychedelic Studies co-executive director Betty Aldworth stated that solving cardiac safety challenges is the central requirement before ibogaine can responsibly reach patients.

Mind-altering substances like psilocybin, LSD, MDMA, and ayahuasca and their therapeutic and cultural use.

First government-funded clinical trials of ibogaine for opioid addiction and PTSD, conducted by the FDA and VA.